Risk Compensation and Clinical Decision Making - The Case of HIV Preexposure Prophylaxis

N Engl J Med. 2019 Feb 7;380(6):510-512. doi: 10.1056/NEJMp1810743.

Authors

Julia L Marcus¹, Kenneth A Katz¹, Douglas S Krakower¹, Sarah K Calabrese¹

Affiliation

¹ From the Department of Population Medicine, Harvard Medical School, and Harvard Pilgrim Health Care Institute (J.L.M., D.S.K.), and the Division of Infectious Diseases, Beth Israel Deaconess Medical Center (D.S.K.) - all in Boston; the Department of Dermatology, Kaiser Permanente San Francisco Medical Center, San Francisco (K.A.K.); and the Department of Psychology, George Washington University, Washington, DC (S.K.C.).

No abstract available

MeSH terms

Anti-HIV Agents / therapeutic use*
Clinical Decision-Making
Condoms* / trends
Female
HIV Infections / prevention & control*
Humans
Male
Patient Acceptance of Health Care
Pre-Exposure Prophylaxis*
Safe Sex*
Sexual Behavior
Sexually Transmitted Diseases / prevention & control
United States

Substances

Anti-HIV Agents

Grants and funding

K01 AI122853/AI/NIAID NIH HHS/United States